What is Roth Capital’s Forecast for ZVRA FY2029 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities research analysts at Roth Capital issued their FY2029 earnings per share estimates for Zevra Therapeutics in a research report issued on Sunday, February 9th. Roth Capital analyst J. Aschoff expects that the company will post earnings per share of $2.26 for the year. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The business had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period in the prior year, the business earned ($0.40) earnings per share.

ZVRA has been the topic of a number of other reports. Canaccord Genuity Group dropped their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Cantor Fitzgerald upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 29th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Zevra Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $21.57.

Zevra Therapeutics Price Performance

ZVRA opened at $7.54 on Tuesday. Zevra Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $9.76. The firm has a 50-day moving average of $8.33 and a 200 day moving average of $8.02. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The firm has a market cap of $402.49 million, a P/E ratio of -3.83 and a beta of 2.00.

Institutional Investors Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ZVRA. International Assets Investment Management LLC grew its position in shares of Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after purchasing an additional 5,940 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after purchasing an additional 2,452 shares during the period. Hunter Associates Investment Management LLC purchased a new position in Zevra Therapeutics during the 3rd quarter valued at about $92,000. XTX Topco Ltd bought a new stake in shares of Zevra Therapeutics during the third quarter valued at about $94,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Zevra Therapeutics in the fourth quarter worth about $94,000. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.